Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: A 4-year study

Antonio Spadaro, Leonardo Punzi, Antonio Marchesoni, Ennio Lubrano, Alessandro Mathieu, Fabrizio Cantini, Ignazio Olivieri, Carlo Salvarani, Raffaele Scarpa, Rossana Scrivo, Roberta Ramonda, Giovanni Porru, Salvatore D'Angelo, Mariagrazia Catanoso, Mariangela Atteno, Guido Valesini

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Objective: TNF-α antagonists, infliximab (INF), etanercept (ETA) and adalimumab (ADA), have been demonstrated to be effective in controlling symptoms in SpAs. The aim of this study was to investigate the possibility of using ADA as a second or third choice. Methods: A retrospective study was conducted in patients with SpA treated with TNF-α blockers who switched from INF or ETA to ADA, for inefficacy or adverse events. Kaplan-Meier survival curves were plotted to determine the rates of continuation of the first treatment (INF or ETA) as compared with the rates of continuation of the second or third treatment with ADA. Results: A total of 1619 patients with SpA were treated with INF (35.3%), ETA (43.7%) and ADA (20.9%). In this cohort, ADA was started in 38 (2.34%) patients as a second anti-TNF-α drug and in 9 (0.56%) as a third anti-TNF-α drug. In SpA patients who failed the first anti-TNF-α, for whatever reason, survival curves for ADA (as a second anti-TNF-α) were significantly better than survival curves for these same patients on their first anti-TNF-α (overall: P

Original languageEnglish
Article numberkeq008
Pages (from-to)1107-1111
Number of pages5
JournalRheumatology
Volume49
Issue number6
DOIs
Publication statusPublished - Mar 11 2010

Fingerprint

Survival
Kaplan-Meier Estimate
Etanercept
Adalimumab
Infliximab
Pharmaceutical Preparations
Retrospective Studies
Therapeutics

Keywords

  • Ankylosing spondylitis
  • Anti-TNF drugs
  • Psoriatic arthritis
  • Spondylarthropathies

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)

Cite this

Spadaro, A., Punzi, L., Marchesoni, A., Lubrano, E., Mathieu, A., Cantini, F., ... Valesini, G. (2010). Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: A 4-year study. Rheumatology, 49(6), 1107-1111. [keq008]. https://doi.org/10.1093/rheumatology/keq008

Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis : A 4-year study. / Spadaro, Antonio; Punzi, Leonardo; Marchesoni, Antonio; Lubrano, Ennio; Mathieu, Alessandro; Cantini, Fabrizio; Olivieri, Ignazio; Salvarani, Carlo; Scarpa, Raffaele; Scrivo, Rossana; Ramonda, Roberta; Porru, Giovanni; D'Angelo, Salvatore; Catanoso, Mariagrazia; Atteno, Mariangela; Valesini, Guido.

In: Rheumatology, Vol. 49, No. 6, keq008, 11.03.2010, p. 1107-1111.

Research output: Contribution to journalArticle

Spadaro, A, Punzi, L, Marchesoni, A, Lubrano, E, Mathieu, A, Cantini, F, Olivieri, I, Salvarani, C, Scarpa, R, Scrivo, R, Ramonda, R, Porru, G, D'Angelo, S, Catanoso, M, Atteno, M & Valesini, G 2010, 'Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: A 4-year study', Rheumatology, vol. 49, no. 6, keq008, pp. 1107-1111. https://doi.org/10.1093/rheumatology/keq008
Spadaro, Antonio ; Punzi, Leonardo ; Marchesoni, Antonio ; Lubrano, Ennio ; Mathieu, Alessandro ; Cantini, Fabrizio ; Olivieri, Ignazio ; Salvarani, Carlo ; Scarpa, Raffaele ; Scrivo, Rossana ; Ramonda, Roberta ; Porru, Giovanni ; D'Angelo, Salvatore ; Catanoso, Mariagrazia ; Atteno, Mariangela ; Valesini, Guido. / Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis : A 4-year study. In: Rheumatology. 2010 ; Vol. 49, No. 6. pp. 1107-1111.
@article{9f2fa72199b0425899e5f2d649af9b05,
title = "Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: A 4-year study",
abstract = "Objective: TNF-α antagonists, infliximab (INF), etanercept (ETA) and adalimumab (ADA), have been demonstrated to be effective in controlling symptoms in SpAs. The aim of this study was to investigate the possibility of using ADA as a second or third choice. Methods: A retrospective study was conducted in patients with SpA treated with TNF-α blockers who switched from INF or ETA to ADA, for inefficacy or adverse events. Kaplan-Meier survival curves were plotted to determine the rates of continuation of the first treatment (INF or ETA) as compared with the rates of continuation of the second or third treatment with ADA. Results: A total of 1619 patients with SpA were treated with INF (35.3{\%}), ETA (43.7{\%}) and ADA (20.9{\%}). In this cohort, ADA was started in 38 (2.34{\%}) patients as a second anti-TNF-α drug and in 9 (0.56{\%}) as a third anti-TNF-α drug. In SpA patients who failed the first anti-TNF-α, for whatever reason, survival curves for ADA (as a second anti-TNF-α) were significantly better than survival curves for these same patients on their first anti-TNF-α (overall: P",
keywords = "Ankylosing spondylitis, Anti-TNF drugs, Psoriatic arthritis, Spondylarthropathies",
author = "Antonio Spadaro and Leonardo Punzi and Antonio Marchesoni and Ennio Lubrano and Alessandro Mathieu and Fabrizio Cantini and Ignazio Olivieri and Carlo Salvarani and Raffaele Scarpa and Rossana Scrivo and Roberta Ramonda and Giovanni Porru and Salvatore D'Angelo and Mariagrazia Catanoso and Mariangela Atteno and Guido Valesini",
year = "2010",
month = "3",
day = "11",
doi = "10.1093/rheumatology/keq008",
language = "English",
volume = "49",
pages = "1107--1111",
journal = "Rheumatology",
issn = "1462-0324",
publisher = ". Published by Oxford University Press on behalf of the British Society for Rheumatology",
number = "6",

}

TY - JOUR

T1 - Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis

T2 - A 4-year study

AU - Spadaro, Antonio

AU - Punzi, Leonardo

AU - Marchesoni, Antonio

AU - Lubrano, Ennio

AU - Mathieu, Alessandro

AU - Cantini, Fabrizio

AU - Olivieri, Ignazio

AU - Salvarani, Carlo

AU - Scarpa, Raffaele

AU - Scrivo, Rossana

AU - Ramonda, Roberta

AU - Porru, Giovanni

AU - D'Angelo, Salvatore

AU - Catanoso, Mariagrazia

AU - Atteno, Mariangela

AU - Valesini, Guido

PY - 2010/3/11

Y1 - 2010/3/11

N2 - Objective: TNF-α antagonists, infliximab (INF), etanercept (ETA) and adalimumab (ADA), have been demonstrated to be effective in controlling symptoms in SpAs. The aim of this study was to investigate the possibility of using ADA as a second or third choice. Methods: A retrospective study was conducted in patients with SpA treated with TNF-α blockers who switched from INF or ETA to ADA, for inefficacy or adverse events. Kaplan-Meier survival curves were plotted to determine the rates of continuation of the first treatment (INF or ETA) as compared with the rates of continuation of the second or third treatment with ADA. Results: A total of 1619 patients with SpA were treated with INF (35.3%), ETA (43.7%) and ADA (20.9%). In this cohort, ADA was started in 38 (2.34%) patients as a second anti-TNF-α drug and in 9 (0.56%) as a third anti-TNF-α drug. In SpA patients who failed the first anti-TNF-α, for whatever reason, survival curves for ADA (as a second anti-TNF-α) were significantly better than survival curves for these same patients on their first anti-TNF-α (overall: P

AB - Objective: TNF-α antagonists, infliximab (INF), etanercept (ETA) and adalimumab (ADA), have been demonstrated to be effective in controlling symptoms in SpAs. The aim of this study was to investigate the possibility of using ADA as a second or third choice. Methods: A retrospective study was conducted in patients with SpA treated with TNF-α blockers who switched from INF or ETA to ADA, for inefficacy or adverse events. Kaplan-Meier survival curves were plotted to determine the rates of continuation of the first treatment (INF or ETA) as compared with the rates of continuation of the second or third treatment with ADA. Results: A total of 1619 patients with SpA were treated with INF (35.3%), ETA (43.7%) and ADA (20.9%). In this cohort, ADA was started in 38 (2.34%) patients as a second anti-TNF-α drug and in 9 (0.56%) as a third anti-TNF-α drug. In SpA patients who failed the first anti-TNF-α, for whatever reason, survival curves for ADA (as a second anti-TNF-α) were significantly better than survival curves for these same patients on their first anti-TNF-α (overall: P

KW - Ankylosing spondylitis

KW - Anti-TNF drugs

KW - Psoriatic arthritis

KW - Spondylarthropathies

UR - http://www.scopus.com/inward/record.url?scp=77953527617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953527617&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/keq008

DO - 10.1093/rheumatology/keq008

M3 - Article

C2 - 20223813

AN - SCOPUS:77953527617

VL - 49

SP - 1107

EP - 1111

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 6

M1 - keq008

ER -